Efficacy of Contractility Modulation Therapy in Patients with Transthyretin Amyloid Cardiomyopathy, Mildly Reduced to Reduced EF and NYHA III and IV: A Multicentric, Prospective Pilot Study for AMY-CCM Registry

This pilot study suggests that CCM therapy is a feasible and potentially effective option for ATTR-CM patients with advanced HF who are not candidates for existing disease-modifying treatments. These findings support the rationale for larger studies, including the ongoing AMY-CCM registry (NCT05167799), to validate CCM's therapeutic role in this population.

Authors

Institutions

Publication Details

Journal
Journal of Cardiovascular Development and Disease
Published
2025-09-25
DOI
https://doi.org/10.3390/jcdd12100380
Citations
1
Primary Topic
Amyloidosis: Diagnosis, Treatment, Outcomes
Type
article
Field-Weighted Citation Impact
0.81
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of Contractility Modulation Therapy in Patients with Transthyretin Amyloid Cardiomyopathy, Mildly Reduced to Reduced EF and NYHA III and IV: A Multicentric, Prospective Pilot Study for AMY-CCM Registry

Antonio Bisignani, L Mazzocchetti, Margherita Cannillo, Matteo Ruzzolini et al.
1 citations
Journal of Cardiovascular Development and Disease
Amyloidosis: Diagnosis, Treatment, Outcomes
0.81
article

Efficacy of Contractility Modulation Therapy in Patients with Transthyretin Amyloid Cardiomyopathy, Mildly Reduced to Reduced EF and NYHA III and IV: A Multicentric, Prospective Pilot Study for AMY-CCM Registry

Antonio Bisignani, L Mazzocchetti, Margherita Cannillo, Matteo Ruzzolini, Cristina Chimenti, Daniele Masarone, R Magnano, Paolo Garrone, Stefano Guarracini, Procolo Marchese, Luigi Cocchiara, Francesca Gennaro, Matteo Bianco, Mauro Biffi, Walter Grosso Marra, Matteo Ziacchi, Giovanni Mazzotta, Carlo Lavalle, Pierfrancesco Grossi, Massimo Di Marco
article en
1 citations

Abstract

This pilot study suggests that CCM therapy is a feasible and potentially effective option for ATTR-CM patients with advanced HF who are not candidates for existing disease-modifying treatments. These findings support the rationale for larger studies, including the ongoing AMY-CCM registry (NCT05167799), to validate CCM's therapeutic role in this population.

Journal of Cardiovascular Development and DiseaseVol. 12(10)
Agostino Gemelli University Polyclinic (IT), Ospedale di Santo Spirito (IT), Ospedale Civile Di Ivrea (IT), Azienda Sanitaria Locale di Asti (IT), Azienda USL di Bologna (IT), Casa di cura Pierangeli (IT), Ospedale Monaldi (IT), Ospedale San Giuseppe (IT), Ospedale San Luigi Gonzaga (IT), University of Naples Federico II (IT), Sapienza University of Rome (IT)
Openalex Percentile: Top 23%
Amyloidosis: Diagnosis, Treatment, Outcomes
0.81
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.